INAB

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Wall Street analysts forecast INAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INAB is 92.00 USD with a low forecast of 36.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

IN8bio Inc revenue for the last quarter amounts to -5.66M USD, decreased -34.53 % YoY.

IN8bio Inc. EPS for the last quarter amounts to -3122000.00 USD, decreased -60.93 % YoY.

IN8bio Inc (INAB) has 18 emplpoyees as of December 15 2025.

Today INAB has the market capitalization of 39.68M USD.